Grade 5 adverse events
. | Placebo + HDAC (N = 86) . | Laromustine + HDAC (N = 177) . | ||
---|---|---|---|---|
n . | % . | n . | % . | |
Adverse events with death | 11 | 13% | 71 | 40% |
Infectious deaths | 3 | 3% | 49 | 28% |
Pulmonary deaths | 0 | 0% | 15 | 8% |
. | Placebo + HDAC (N = 86) . | Laromustine + HDAC (N = 177) . | ||
---|---|---|---|---|
n . | % . | n . | % . | |
Adverse events with death | 11 | 13% | 71 | 40% |
Infectious deaths | 3 | 3% | 49 | 28% |
Pulmonary deaths | 0 | 0% | 15 | 8% |
N indicates number of patients; and n, number of deaths.